Polatuzumab vedotin-piiq plus R-CHP can reduce the need for any subsequent lines of therapy for patients with diffuse large B-cell lymphoma, according to an expert from The University of Texas MD Anderson Cancer Center.
Christopher Flowers, MD, MS
Advertisement
Articles by Christopher Flowers, MD, MS
Geriatric assessments have now been recommended as part of the standard evaluation of an older adult considering cancer therapy.
Advertisement
Latest Updated Articles
The Role of the Comprehensive Geriatric Assessment in the Evaluation of the Older Cancer PatientPublished: November 14th 2019 | Updated:
Polatuzumab Vedotin Regimen Yields ‘Meaningful’ Benefit in DLBCL, Expert SaysPublished: April 19th 2023 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
FDA Approves Revumenib in R/R NPM1-Mutant AML
3
Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment
4
Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology
5
